Product Description
Triazolam is a triazolobenzodiazepine with hypnotic properties, advocated for use in acute or chronic insomnia, situational insomnia in hospitalised patients, and insomnia associated with other disease states. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/6114852/)
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | Chile | Colombia | Denmark | Dominican Republic | Finland | Germany | Greece | Hong Kong | Iceland | Ireland | Italy | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Mexico | New Zealand | Pakistan | Peru | Portugal | Spain | Sweden | Switzerland | Taiwan | United States | Venezuela
Approved Indications: Insomnia
Known Adverse Events: Ataxia | Dizziness
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|